Announcements
- Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
- Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
- Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
- Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
- Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
- Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
- Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
More ▼
Key statistics
As of last trade Crinetics Pharmaceuticals Inc (6Z4:BER) traded at 50.50, 0.00% below its 52-week high of 50.50, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 49.20 |
---|---|
High | 50.50 |
Low | 49.00 |
Bid | 50.00 |
Offer | 51.50 |
Previous close | 48.40 |
Average volume | 102.22 |
---|---|
Shares outstanding | 78.86m |
Free float | 75.71m |
P/E (TTM) | -- |
Market cap | 4.25bn USD |
EPS (TTM) | -3.77 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 15:58 BST.
More ▼